News Headlines

31. CDMO Alcami Announces Plans To Add Capacity For Sterile Drug Product Development And Manufacturing 12/18/2019

    Alcami, a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biologics industries, plans to expand the company’s current operations in North Charleston, South Carolina.

32. Symbiosis Invests £1.5M In UK Facility Expansion 12/17/2019

    Fast-growing specialist sterile manufacturing and Contract Manufacturing Organisation (CMO) Symbiosis Pharmaceutical Services (Symbiosis), has expanded its sterile biologics manufacturing facility in Scotland, UK by 25%.

33. Recipharm Partners With Aptahem For Formulation Of Apta-1 Drug Candidate 12/17/2019

    Recipharm, the contract development and manufacturing organisation (CDMO) has partnered with biotechnology company Aptahem, for the formulation of Apta-1 drug candidate.

34. PCI Pharma Services Announces Major Manufacturing Facility Investment In Wales 12/11/2019

    PCI Pharma Services (PCI), a leading pharmaceutical and biopharmaceutical global outsourcing solutions provider, today announced it has begun an expansion of its Tredegar facility in Wales, UK to enhance its high potent drug manufacturing and development capabilities, including both clinical and commercial supply.

35. Pelican BioThermal Achieves International ISO Accreditation 12/11/2019

    Pelican BioThermal, the global name in temperature-controlled packaging, announces it has achieved accreditation for technical competency within its laboratories in Europe and the US.

36. Recipharm Invests In Its US Inhalation Development Service 12/10/2019

    Recipharm, the contract development and manufacturing organisation (CDMO), has invested USD 450,000 into its Research Triangle Park (RTP), North Carolina, US facility to install a SprayVIEW system that will support inhalation and nasal product development.

37. Merck To Acquire ArQule, Advancing Leadership In Oncology 12/9/2019

    Merck known as MSD outside the United States and Canada, and ArQule, Inc. today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire ArQule for $20 per share in cash for an approximate total equity value of $2.7B.

38. Sanofi To Acquire Synthorx To Bolster Its Immuno-Oncology Pipeline For $2.5B 12/9/2019

    Sanofi and Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company focused on prolonging and improving the lives of people suffering from cancer and autoimmune disorders, entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Synthorx for $68 per share in cash, which represents an aggregate equity value of approximately $2.5 billion (on a fully diluted basis).

39. Autoimmune Technologies Announces New Subsidiary To Develop Novel Antibody And Allogeneic Somatic Stem Cell Therapeutics For The Treatment Of Invasive Candidiasis And Other Infectious Disease 12/9/2019

    Autoimmune Technologies LLC, a biotechnology company developing diagnostics and therapies for non-infectious and infectious disease, has established a new subsidiary, Stadius Biopharma LLC, to focus on proprietary anti-infective antibody therapeutics for diseases that are inadequately addressed by current standard-of-care medicines.

40. Thermo Fisher Scientific Opens $90 Million Viral Vector Manufacturing Site in Massachusetts 12/5/2019

    New facility will create 200 new jobs and accelerate commercialization of gene and cell therapies.